LU91006I2 - Neupopeg-pegfilgrastim et ses dérivés pharmaceutiquement acceptables - Google Patents

Neupopeg-pegfilgrastim et ses dérivés pharmaceutiquement acceptables

Info

Publication number
LU91006I2
LU91006I2 LU91006C LU91006C LU91006I2 LU 91006 I2 LU91006 I2 LU 91006I2 LU 91006 C LU91006 C LU 91006C LU 91006 C LU91006 C LU 91006C LU 91006 I2 LU91006 I2 LU 91006I2
Authority
LU
Luxembourg
Prior art keywords
neupopeg
pegfilgrastim
ses dérivés
pharmaceutiquement acceptables
compositions
Prior art date
Application number
LU91006C
Other languages
English (en)
French (fr)
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23250903&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91006(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of LU91006I2 publication Critical patent/LU91006I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LU91006C 1994-10-12 2003-01-29 Neupopeg-pegfilgrastim et ses dérivés pharmaceutiquement acceptables LU91006I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/321,510 US5824784A (en) 1994-10-12 1994-10-12 N-terminally chemically modified protein compositions and methods
PCT/US1995/001729 WO1996011953A1 (en) 1994-10-12 1995-02-08 N-terminally chemically modified protein compositions and methods

Publications (1)

Publication Number Publication Date
LU91006I2 true LU91006I2 (en) 2003-03-31

Family

ID=23250903

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91006C LU91006I2 (en) 1994-10-12 2003-01-29 Neupopeg-pegfilgrastim et ses dérivés pharmaceutiquement acceptables

Country Status (19)

Country Link
US (7) US5824784A (OSRAM)
EP (5) EP1564219A1 (OSRAM)
JP (8) JP3177251B2 (OSRAM)
KR (2) KR100248111B1 (OSRAM)
CN (4) CN101381409B (OSRAM)
AT (2) ATE277078T1 (OSRAM)
CA (3) CA2472085A1 (OSRAM)
DE (3) DE69509628T2 (OSRAM)
DK (1) DK0733067T3 (OSRAM)
ES (2) ES2131811T3 (OSRAM)
GR (1) GR3030526T3 (OSRAM)
IL (3) IL112585A (OSRAM)
LU (1) LU91006I2 (OSRAM)
MX (1) MX9602259A (OSRAM)
NL (1) NL300106I2 (OSRAM)
NZ (1) NZ281469A (OSRAM)
PT (1) PT822199E (OSRAM)
WO (1) WO1996011953A1 (OSRAM)
ZA (1) ZA951008B (OSRAM)

Families Citing this family (563)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2006596C (en) * 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US20020177688A1 (en) * 1988-12-22 2002-11-28 Kirin-Amgen, Inc., Chemically-modified G-CSF
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
PT726778E (pt) * 1994-02-08 2001-12-28 Amgen Inc Sistema de administracao oral de proteinas g-csf modificadas quimicamente
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1996041813A2 (en) * 1994-11-09 1996-12-27 Offord Robin E Functionalized polymers for site-specific attachment
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
JP2000507917A (ja) 1995-11-02 2000-06-27 シェーリング コーポレイション 持続的低用量サイトカイン注入治療
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
WO1998024477A1 (en) 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
JP2001508783A (ja) * 1997-01-29 2001-07-03 ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー Ｐｅｇ化法
WO1998055500A1 (en) 1997-06-06 1998-12-10 Kyowa Hakko Kogyo Co., Ltd. Chemically modified polypeptides
WO2000042175A1 (en) 1999-01-14 2000-07-20 Bolder Biotechnology Inc. Methods for making proteins containing free cysteine residues
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
DE69838552T2 (de) * 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US6017876A (en) * 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
ES2224649T3 (es) * 1998-04-28 2005-03-01 Applied Research Systems Ars Holding N.V. Conjugados de poliol-ifn-beta.
AU766597B2 (en) * 1998-05-15 2003-10-16 Schering Corporation Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis C infection
NL1009601C2 (nl) * 1998-07-09 2000-01-11 Univ Utrecht Verbinding welke de binding van een eiwit aan mestcellen kan remmen, toepassing van de verbinding voor de bereiding van een geneesmiddel, een farmaceutisch preparaat, een werkwijze voor het diagnostiseren van een ziekte en een selectiewerkwijze.
CA2335096A1 (en) * 1998-07-16 2000-01-27 Hyseq, Inc. Methods and materials relating to novel cd39-like polypeptides
PT2316475T (pt) * 1998-08-06 2017-12-21 Univ Duke Uricase tetramérica isolada
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
EP2599503B1 (en) 1998-10-16 2017-05-17 Biogen MA Inc. Polymer conjugates of interferon beta-1A and uses thereof
DK1121382T3 (da) * 1998-10-16 2006-11-13 Biogen Idec Inc Interferon-beta-fusionsproteiner og deres anvendelser
ATE348163T1 (de) 1998-10-23 2007-01-15 Amgen Inc Thrombopoietin substitute
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
JP2002531089A (ja) * 1998-11-30 2002-09-24 イーライ・リリー・アンド・カンパニー 赤血球産生性化合物
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
CN1376164A (zh) * 1999-01-29 2002-10-23 霍夫曼-拉罗奇有限公司 Gcsf缀合物
EP1369429A1 (en) * 1999-01-29 2003-12-10 F. Hoffmann-La Roche Ag GCSF conjugates
AU2824700A (en) * 1999-03-01 2000-09-21 Kyowa Hakko Kogyo Co. Ltd. Chemically modified g-csf preparations
US6485718B1 (en) 1999-04-13 2002-11-26 Pharmacia Corporation Site specific ligation of proteins to synthetic particles
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US8106098B2 (en) * 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US7160924B2 (en) * 2002-07-19 2007-01-09 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US7074878B1 (en) 1999-12-10 2006-07-11 Harris J Milton Hydrolytically degradable polymers and hydrogels made therefrom
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
HUP0203751A3 (en) 2000-01-10 2005-01-28 Maxygen Holdings Ltd Redwood C G-csf conjugates
US7049761B2 (en) * 2000-02-11 2006-05-23 Altair Engineering, Inc. Light tube and power supply circuit
DE60138364D1 (de) 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
TR200401573T4 (tr) 2000-02-29 2004-08-23 Pfizer Products Inc. Stabilize edilmiş granülosit koloni uyarıcı faktör
US20020064820A1 (en) * 2000-03-13 2002-05-30 Jean-Michel Dayer Apo-A-I regulation of T-cell signaling
AU2001289307A1 (en) * 2000-04-06 2001-10-23 Pharmacia Corporation Chemically-modified myelopoietin conjugates
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
EP1280924A2 (en) * 2000-04-14 2003-02-05 University of South Carolina Research Foundation Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses
ES2260219T3 (es) 2000-04-21 2006-11-01 Amgen Inc. Derivados de peptidos apo-ai/aii.
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
EP1307216A4 (en) * 2000-07-12 2005-01-12 Gryphon Therapeutics Inc MODIFIED POLYMERIC BIOACTIVE SYNTHETIC CHEMOKINES AND METHODS OF MAKING AND USING SAME
CZ2003678A3 (cs) * 2000-09-08 2004-03-17 Gryphon Therapeutics, Inc. Syntetické proteiny stimulující erytropoézu
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
ES2367891T3 (es) 2000-09-29 2011-11-10 Schering Corporation Interleucina-10 pegilada.
EP1333036B1 (en) * 2000-10-16 2009-01-21 Chugai Seiyaku Kabushiki Kaisha Peg-modified erythropoietin
CN101584867A (zh) * 2000-10-31 2009-11-25 瑟莫迪克斯药品公司 提高生物活性分子传递的方法和组合物
AU2002212108A1 (en) * 2000-11-02 2002-05-15 Maxygen Aps Single-chain multimeric polypeptides
CN1321134C (zh) * 2000-11-23 2007-06-13 赵剑 一种生物活性蛋白质的非均一制品及其制备方法
JP2004515533A (ja) * 2000-12-14 2004-05-27 アミリン・ファーマシューティカルズ，インコーポレイテッド 代謝障害を治療するためのペプチドｙｙおよびペプチドｙｙアゴニスト
US7053150B2 (en) 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
TW593427B (en) * 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
JP4656814B2 (ja) * 2000-12-20 2011-03-23 エフ．ホフマン−ラ ロシュ アーゲー エリスロポエチンコンジュゲート
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
EP1392731B1 (en) * 2001-02-06 2008-07-02 Merk Patent Gmbh Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
MXPA03007619A (es) 2001-02-27 2003-12-04 Maxygen Aps Nuevas moleculas similares a interferon beta.
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US20030203865A1 (en) * 2001-04-30 2003-10-30 Pierrot Harvie Lipid-comprising drug delivery complexes and methods for their production
US7247618B2 (en) * 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
ATE549354T1 (de) 2001-05-11 2012-03-15 Amgen Inc Peptide und damit zusammenhängende an tall-1 bindende moleküle
CA2450985A1 (en) * 2001-06-28 2003-01-09 Mountain View Pharmaceuticals, Inc. Polymer stabilized proteinases
JP4444652B2 (ja) 2001-07-11 2010-03-31 マキシゲン・ホールディングズ・リミテッド Ｇ−ｃｓｆ結合体
US20040077835A1 (en) * 2001-07-12 2004-04-22 Robin Offord Chemokine receptor modulators, production and use
WO2003030923A1 (en) * 2001-10-05 2003-04-17 Intermune, Inc. Method of treating hepatitis virus infection with a multiphasic interferon delivery profile
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7056500B2 (en) 2001-10-18 2006-06-06 Nektar Therapeutics Al, Corporation Polymer conjugates of opioid antagonists
WO2003043651A1 (fr) * 2001-11-19 2003-05-30 Kyowa Hakko Kogyo Co., Ltd. Medicament mobilisant les cellules souches totipotentes d'un tissu dans le sang peripherique
JP2005525302A (ja) * 2001-11-20 2005-08-25 ファルマシア・コーポレーション 化学的に修飾されたヒト成長ホルモンコンジュゲート
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
KR100480432B1 (ko) * 2001-12-04 2005-04-06 선바이오(주) Ｇ-ｃｓｆ와 폴리에틸렌글리콜 유도체의 배합체
US20050095224A1 (en) * 2001-12-07 2005-05-05 Ramachandran Radhakrishnan Compositions and method for treating hepatitis virus infection
WO2003059988A2 (en) 2002-01-14 2003-07-24 The General Hospital Corporation Biodegradable polyketal polymers and methods for their formation and use
SK3102004A3 (sk) * 2002-01-18 2005-01-03 Biogen Idec MA Inc. Polyalkylénglykol s časťou na konjugáciu biologicky aktívnej zlúčeniny
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
DE60335639D1 (de) * 2002-06-14 2011-02-17 Amylin Pharmaceuticals Inc Prävention und/oder behandlung von colitis ulcerosa mit pyy oder pyyä3-36ü
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
AU2003254023A1 (en) * 2002-07-19 2004-02-09 The General Hospital Corporation Oxime conjugates and methods for their formation and use
JP2006508056A (ja) 2002-08-28 2006-03-09 イミュネックス・コーポレーション 心臓血管疾患を治療するための組成物および方法
EA200500475A1 (ru) * 2002-09-09 2005-10-27 Нектар Терапеутикс Ал, Корпорейшн Водорастворимые полимерные алканалы
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
AU2003273413A1 (en) 2002-10-08 2004-05-04 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
JP2004196770A (ja) * 2002-10-24 2004-07-15 Effector Cell Institute Inc 樹状細胞前駆体の血中レベル上昇剤
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
TWI281864B (en) * 2002-11-20 2007-06-01 Pharmacia Corp N-terminally monopegylated human growth hormone conjugates and process for their preparation
JP2006519170A (ja) * 2002-12-26 2006-08-24 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド サイトカイン、ケモカイン、増殖因子、ポリペプチドホルモン、およびレセプター結合活性が保存されたそのアンタゴニストのポリマー結合体
AU2003292696A1 (en) 2002-12-26 2004-08-10 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
MXPA05006944A (es) * 2002-12-26 2005-12-14 Mountain View Pharmaceuticals Conjugados polimericos de interferon-beta cion potencia biologica aumentada.
US8034900B2 (en) * 2002-12-30 2011-10-11 Amylin Pharmaceuticals, Inc. Water-soluble thioester and selenoester compounds and methods for making and using the same
US7803362B2 (en) * 2003-01-24 2010-09-28 Synageva Biopharma Corp. Glycosylated interferon alpha
CA2516552A1 (en) * 2003-02-26 2004-09-10 Intermune, Inc. Polyethylene glycol modified interferon compositions and methods of use thereof
WO2004078127A2 (en) * 2003-02-28 2004-09-16 Intermune, Inc. Continuous delivery methods for treating hepatitis virus infection
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
ES2564103T3 (es) 2003-03-05 2016-03-17 Halozyme, Inc. Glicoproteína hialuronidasa soluble (sHASEGP), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden
EP1608688B1 (en) 2003-03-14 2013-02-27 BioGeneriX AG Branched water-soluble polymers and their conjugates
AU2004224466B2 (en) * 2003-03-28 2008-01-03 Biopolymed Inc. Biologically active material conjugated with biocompatible polymer with 1:1 complex, preparation method thereof and pharmaceutical composition comprising the same
US20060134736A1 (en) * 2003-03-28 2006-06-22 Jacobs John W Human growth hormone conjugated with biocompatible polymer
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
CA2520875A1 (en) 2003-03-31 2004-10-21 Xencor, Inc. Methods for rational pegylation of proteins
US7642340B2 (en) 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
CN1777440A (zh) 2003-04-11 2006-05-24 Pr药品有限公司 位点特异性蛋白质偶联物的制备方法
EP1613274B1 (en) 2003-04-15 2010-03-03 GlaxoSmithKline LLC Human il-18 substitution mutants and their conjugates
ATE433759T1 (de) 2003-04-18 2009-07-15 Biogen Idec Inc Polymerkonjugiertes glycosiliertes neublastin
US20070172446A1 (en) 2003-05-16 2007-07-26 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
KR101131411B1 (ko) 2003-07-22 2012-07-05 넥타르 테라퓨틱스 중합체 알코올로부터 관능화된 중합체의 제조 방법
ES2383328T3 (es) 2003-07-25 2012-06-20 Amgen, Inc Métodos relacionados con LDCAM y CRTAM
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
EP1666496B1 (en) 2003-08-25 2014-03-12 Toray Industries, Inc. Interferon-beta composite
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
SI1675622T1 (sl) 2003-09-17 2017-09-29 Nektar Therapeutics Večkraka polimerna predzdravila
MXPA06003141A (es) * 2003-09-22 2006-06-05 Boehringer Ingelheim Int Peptidos macrociclicos activos contra el virus de la hepatitis c.
ES2737837T3 (es) 2003-10-09 2020-01-16 Ambrx Inc Derivados poliméricos
EP1673387B1 (en) 2003-10-10 2010-09-15 Novo Nordisk A/S Il-21 derivatives
EP2327723A3 (en) 2003-10-10 2012-06-27 Xencor, Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
TW201245229A (en) 2003-10-14 2012-11-16 Hoffmann La Roche Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
EP2633866A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
WO2005040758A2 (en) * 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US7220407B2 (en) * 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
EP1725572B1 (de) 2003-11-05 2017-05-31 AGCT GmbH Makromolekulare nukleotidverbindungen und methoden zu deren anwendung
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
WO2005053730A1 (ja) * 2003-12-05 2005-06-16 Kirin Beer Kabushiki Kaisha 末期心不全治療剤
WO2005067963A1 (en) * 2003-12-23 2005-07-28 Intermune, Inc. Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
NZ548123A (en) 2004-01-08 2010-05-28 Novo Nordisk As O-linked glycosylation of peptides
EP1730167B1 (en) * 2004-01-21 2011-01-12 Boehringer Ingelheim International GmbH Macrocyclic peptides active against the hepatitis c virus
NZ548255A (en) 2004-02-02 2010-10-29 Ambrx Inc Modified human interferon polypeptides and their uses
IN2012DN03921A (OSRAM) 2004-02-11 2015-09-04 Amylin Pharmaceuticals Inc
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
EP1789440A4 (en) 2004-02-11 2008-03-12 Amylin Pharmaceuticals Inc REASONS FOR THE FAMILY OF PANCREATIC POLYPEPTIDES AND POLYPEPTIDES CONTAINING THEM
CA2556339A1 (en) * 2004-03-01 2005-09-15 David Ray Filpula Interferon-beta polymer conjugates
MXPA06010764A (es) * 2004-03-23 2006-12-15 Amgen Inc Metodos y composiciones de proteinas quimicamente modificadas.
JP2008505853A (ja) 2004-04-13 2008-02-28 クインテセンス バイオサイエンシーズ インコーポレーティッド 細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体
EP1586334A1 (en) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
AU2005245918A1 (en) 2004-05-19 2005-12-01 F. Hoffmann-La Roche Ag Interferon-alpha polypeptides and conjugates
WO2005123113A2 (en) * 2004-06-14 2005-12-29 Intermune, Inc. Interferon compositions and methods of use thereof
KR20070034512A (ko) 2004-06-18 2007-03-28 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
CN101845091A (zh) 2004-06-25 2010-09-29 武田药品工业株式会社 转移素衍生物及其用途
AU2005260664A1 (en) * 2004-06-30 2006-01-12 Egen Corporation Pegylated interferon alpha-1b
JP2008505928A (ja) * 2004-07-08 2008-02-28 アムジェン　インコーポレーテッド 治療用ペプチド
US20080300173A1 (en) * 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
AU2009212311B8 (en) 2004-07-21 2013-05-30 Ambrx, Inc. Modified leptin polypeptides and their uses
EP1771573A4 (en) 2004-07-21 2009-02-18 Ambrx Inc BIOSYNTHETIC POLYPEPTIDES OBTAINED FROM NON-NATURALLY CITED AMINO ACIDS
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP4959566B2 (ja) 2004-08-19 2012-06-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド トランスホーミング増殖因子βファミリータンパク質の折りたたみ
EP2335713A3 (en) 2004-08-19 2011-11-02 Biogen Idec MA Inc. Neublastin variants
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
US20060204512A1 (en) 2004-09-23 2006-09-14 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
DK1797127T3 (en) 2004-09-24 2017-10-02 Amgen Inc Modified Fc molecules
EP2586456B1 (en) 2004-10-29 2016-01-20 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (FGF)
WO2006055260A2 (en) 2004-11-05 2006-05-26 Northwestern University Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders
JP5743371B2 (ja) 2004-12-13 2015-07-01 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 膵臓ポリペプチドファミリーモチーフ、ポリペプチドおよびこれらを含む方法
ATE541934T1 (de) * 2004-12-22 2012-02-15 Ambrx Inc Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon
WO2006073846A2 (en) 2004-12-22 2006-07-13 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
NZ555386A (en) * 2004-12-22 2011-01-28 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid
CN104803865A (zh) 2004-12-22 2015-07-29 Ambrx公司 含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及其用途
JP2008525473A (ja) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 修飾されたヒト成長ホルモン
JP4951527B2 (ja) 2005-01-10 2012-06-13 バイオジェネリックス アーゲー 糖ｐｅｇ化顆粒球コロニー刺激因子
MX2007008982A (es) 2005-01-25 2007-12-06 Cell Therapeutics Inc Conjugados de proteinas biologicamente activas que tienen una vida media modificada in vivo.
KR20070099013A (ko) * 2005-01-31 2007-10-08 주식회사 에펙타 세포연구소 면역 증강제
US7402730B1 (en) 2005-02-03 2008-07-22 Lexicon Pharmaceuticals, Inc. Knockout animals manifesting hyperlipidemia
WO2006086769A2 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
WO2006094530A1 (en) * 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
WO2007010552A2 (en) * 2005-03-17 2007-01-25 Serum Institute Of India Limited N- terminal peg conjugate of erythropoietin
EP2258382A3 (en) 2005-03-31 2014-05-14 Amylin Pharmaceuticals, LLC Amylin and amylin agonists for treating psychiatric diseases and disorders
EP1868652A2 (en) 2005-04-05 2007-12-26 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Method for shielding functional sites or epitopes on proteins
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP1871874B1 (en) 2005-04-11 2015-04-08 Crealta Pharmaceuticals LLC Variant forms of urate oxidase and use thereof
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
AU2006299901A1 (en) 2005-05-18 2007-04-19 Maxygen, Inc. Evolved interferon-alpha polypeptides
US20080255026A1 (en) 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
KR20080027291A (ko) * 2005-06-01 2008-03-26 맥시겐 홀딩스 엘티디 피이지화된 지-씨에스에프 폴리펩타이드 및 그 제조방법
JP2008545754A (ja) * 2005-06-01 2008-12-18 アルザ・コーポレーシヨン ポリエチレングリコール試薬をアシル化するためのバイオコンジュゲーション反応
WO2007009208A1 (en) * 2005-06-02 2007-01-25 Cangene Corporation Poly(ethylene glocol) modified human gm-csf with increased biological activity
MX2007015058A (es) * 2005-06-03 2008-01-28 Ambrx Inc Moleculas de interferon humano mejoradas y sus usos.
EP1893240A2 (en) * 2005-06-13 2008-03-05 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
KR100694994B1 (ko) * 2005-06-13 2007-03-14 씨제이 주식회사 사람 과립구 콜로니 형성인자 동종체
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
BRPI0613142A2 (pt) 2005-06-17 2010-12-21 Novartis Ag uso de sangliferina em hcv
US7695710B2 (en) * 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
KR20080037656A (ko) * 2005-06-20 2008-04-30 펩젠 코포레이션 저독성의 장시간 순환하는 사람 인터페론-알파 유사체 및인터페론 타우의 키메라
ATE524509T1 (de) 2005-07-18 2011-09-15 Nektar Therapeutics Verzweigte funktionalisierte polymere unter verwendung von verzweigten polyolen als kernen
KR100735784B1 (ko) 2005-07-20 2007-07-06 재단법인 목암생명공학연구소 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
NZ565059A (en) 2005-07-25 2011-08-26 Intermune Inc Novel macrocyclic inhibitors of hepatitus C virus replication
WO2007015591A1 (en) * 2005-08-02 2007-02-08 Cheil Industries Inc. Epoxy resin composition for packaging semiconductor device
MX2008001706A (es) * 2005-08-04 2008-04-07 Nektar Therapeutics Al Corp Conjugados de una porcion g-csf y un polimero.
AU2006279680B2 (en) * 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
KR101285904B1 (ko) 2005-08-18 2013-07-15 암브룩스, 인코포레이티드 ｔＲＮＡ 조성물 및 이의 용도
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
JP5693817B2 (ja) 2005-08-19 2015-04-01 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 糖尿病の治療法および体重の減少法
BRPI0617274A2 (pt) 2005-10-11 2011-07-19 Intermune Inc compostos e métodos para a inibição de replicação viral de hepatite c
US20090304754A1 (en) * 2005-10-12 2009-12-10 Srebrenka Robic Pegylated glutenase polypeptides
CA2626082C (en) 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
US20080171696A1 (en) * 2005-10-21 2008-07-17 Avigenics, Inc. Pharmacodynamically enhanced therapeutic proteins
CA2622210A1 (en) * 2005-10-21 2007-04-26 Avigenics, Inc. Glycolated and glycosylated poultry derived therapeutic proteins
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
CA2625540C (en) * 2005-11-08 2017-03-21 Ambrx, Inc. Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
CN101454461A (zh) * 2005-11-16 2009-06-10 Ambrx公司 包括非天然氨基酸的方法和组合物
NZ568578A (en) * 2005-12-14 2011-10-28 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
JP5738516B2 (ja) 2005-12-30 2015-06-24 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド 心機能改善のためのニューレグリンの徐放
KR101418607B1 (ko) 2006-01-12 2014-07-14 호쿠산 가부시키가이샤 인터페론 α를 포함하는 구강 조성물
CN100475270C (zh) * 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
AR059193A1 (es) 2006-01-31 2008-03-12 Bayer Schering Pharma Ag Modulacion de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias
CN103030801B (zh) 2006-02-21 2015-07-22 尼克塔治疗公司 嵌段可降解聚合物及由其制备的轭合物
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
US8278421B2 (en) 2006-03-20 2012-10-02 Xoma Techolology Ltd. Human antibodies specific for gastrin materials and methods
CA2648053A1 (en) * 2006-03-31 2007-10-11 Centocor, Inc. Binding partners with immunoglobulin domains modified to have extended half-life
EP2007789B1 (en) 2006-04-11 2015-05-20 Novartis AG Spirocyclic HCV/HIV inhibitors and their uses
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
WO2007133778A2 (en) * 2006-05-12 2007-11-22 Amylin Pharmaceuticals, Inc. Methods to restore glycemic control
CN103255162A (zh) 2006-05-19 2013-08-21 格利科菲公司 促红细胞生成素组合物
RU2008145084A (ru) 2006-05-24 2010-06-27 Ново Нордиск Хелс Кеа Аг (Ch) Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
EP2044097A4 (en) * 2006-06-23 2010-10-06 Quintessence Biosciences Inc Modified ribonucleases
US20080096900A1 (en) 2006-06-26 2008-04-24 Amgen Inc. Methods for treating atherosclerosis
US8298801B2 (en) * 2006-07-17 2012-10-30 Quintessence Biosciences, Inc. Methods and compositions for the treatment of cancer
US20080248959A1 (en) 2006-07-21 2008-10-09 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
EP2043616B1 (en) * 2006-07-25 2016-01-27 Lipoxen Technologies Limited N-terminal conjugation of polysialic acid to proteins
GB0615067D0 (en) * 2006-07-28 2006-09-06 Ttp Communications Ltd Reconfigurable signal processing scheme
KR20090046923A (ko) * 2006-08-04 2009-05-11 프로롱 파마슈티컬스, 인크. 수식된 에리스로포이에틴
ITMI20061624A1 (it) * 2006-08-11 2008-02-12 Bioker Srl Mono-coniugati sito-specifici di g-csf
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
AU2007291501B2 (en) * 2006-08-31 2012-07-12 F. Hoffmann-La Roche Ag Method for the production of insulin-like growth factor-I
AU2007292892B9 (en) * 2006-09-08 2013-02-28 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
CN106008699A (zh) 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
AU2007292893B2 (en) * 2006-09-08 2012-03-01 Ambrx, Inc. Suppressor tRNA transcription in vertebrate cells
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
US20080081031A1 (en) 2006-09-28 2008-04-03 Schering Corporation Use of Pegylated IL-10 to Treat Cancer
JP2010505874A (ja) 2006-10-03 2010-02-25 ノヴォ ノルディスク アー／エス ポリペプチドコンジュゲートの精製方法
WO2008060780A2 (en) * 2006-10-04 2008-05-22 Novo Nordisk A/S Glycerol linked pegylated sugars and glycopeptides
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
TW200833840A (en) 2006-10-25 2008-08-16 Amgen Inc Toxin peptide therapeutic agents
JO3048B1 (ar) 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها
KR101079993B1 (ko) * 2006-11-17 2011-11-04 동아제약주식회사 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
CA2670471A1 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
KR101503937B1 (ko) 2006-12-08 2015-03-18 렉시컨 파마슈티컬스 인코퍼레이티드 Ａｎｇｐｔｌ３ 에 대한 단일클론 항체
WO2008097497A2 (en) 2007-02-02 2008-08-14 Adnexus, A Bristol-Myers Squibb R & D Company Vegf pathway blockade
CN101245109B (zh) * 2007-02-12 2011-12-14 杭州九源基因工程有限公司 一种聚乙二醇单修饰的重组人粒细胞集落刺激因子突变体及其制备方法
EP2068909B1 (en) 2007-03-30 2012-04-25 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
AU2008237411B2 (en) 2007-04-03 2013-10-03 Ratiopharm Gmbh Methods of treatment using glycopegylated G-CSF
JP2008266219A (ja) * 2007-04-20 2008-11-06 National Institute Of Advanced Industrial & Technology リジン及びシステイン残基を含まないタンパク質
JP5583005B2 (ja) 2007-05-01 2014-09-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血管新生を増大させるための組成物および方法
CN101675071B (zh) 2007-05-02 2014-06-18 Ambrx公司 经修饰干扰素β多肽和其用途
EP2738257A1 (en) 2007-05-22 2014-06-04 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
WO2008151258A2 (en) * 2007-06-04 2008-12-11 Neose Technologies, Inc. O-linked glycosylation using n-acetylglucosaminyl transferases
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
US20110159523A1 (en) * 2007-06-27 2011-06-30 Cedars-Sinai Medical Center N-terminal specific chemical labeling for proteomics applications
PL2489731T3 (pl) 2007-07-26 2015-01-30 Amgen Inc Zmodyfikowane enzymy acylotransferaza lecytyna-cholesterol
CN101352573B (zh) * 2007-07-27 2011-02-09 杭州九源基因工程有限公司 聚乙二醇单修饰的重组人集落细胞刺激因子赖氨酸缺陷体
AU2008287063B2 (en) 2007-08-09 2013-10-24 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
BRPI0815975B8 (pt) 2007-08-27 2021-05-25 Biogenerix Ag preparação aquosa, recipiente farmacêutico, processo para preparar uma preparação aquosa, e, uso de uma preparação aquosa
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
WO2009046015A2 (en) * 2007-09-30 2009-04-09 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
JP2010540681A (ja) * 2007-10-08 2010-12-24 クインテッセンス バイオサイエンシズ，インコーポレーテッド リボヌクレアーゼに基づく治療のための組成物及び方法
US8440787B2 (en) * 2007-10-23 2013-05-14 Nektar Therapeutics Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom
ES2632504T3 (es) 2007-11-20 2017-09-13 Ambrx, Inc. Polipéptidos de insulina modificados y sus usos
WO2009073977A1 (en) * 2007-12-13 2009-06-18 Biovectra Inc. Polypeptides modified by protein trans-splicing technology
AU2008345183B2 (en) * 2007-12-27 2014-08-21 Baxalta GmbH Method and compositions for specifically detecting physiologically acceptable polymer molecules
WO2009120396A2 (en) * 2008-01-08 2009-10-01 The University Of California Compositions and methods for regulating erythropoientin expression and ameliorating anemia and stimulating erythropoiesis
EP2242505A4 (en) * 2008-01-08 2012-03-07 Biogenerix Ag GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES
US20090183503A1 (en) * 2008-01-18 2009-07-23 Alberto Verdesi Exhaust apparatus
HUE032074T2 (en) 2008-01-18 2017-08-28 Biomarin Pharm Inc Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
US8629104B2 (en) 2008-02-18 2014-01-14 Jiangsu Hengrui Medicine Co. Ltd. G-CSF and water-soluble polymer conjugate
WO2009108806A1 (en) 2008-02-27 2009-09-03 Novo Nordisk A/S Conjugated factor viii molecules
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
JP5458416B2 (ja) * 2008-04-03 2014-04-02 バイオスティード ジーン エクスプレッション テック． カンパニー リミテッド 二本鎖ポリエチレングリコール化成長ホルモン、その製造方法およびその使用
BRPI0911266A2 (pt) * 2008-04-03 2015-09-29 Hoffmann La Roche ensaio de fator de crescimento similar à insulina peguilado
NZ601248A (en) 2008-04-14 2014-06-27 Halozyme Inc Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
WO2009143285A2 (en) 2008-05-21 2009-11-26 Amylin Pharmaceuticals, Inc. Exendins to lower cholestrol and triglycerides
CN102099373A (zh) 2008-05-22 2011-06-15 百时美施贵宝公司 基于纤连蛋白的多价支架结构域蛋白
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
GB0811743D0 (en) 2008-06-26 2008-07-30 Hemosol Biopharma Inc Composition
EP2671891A3 (en) 2008-06-27 2014-03-05 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
CN106928339A (zh) 2008-07-23 2017-07-07 Ambrx 公司 经修饰的牛g‑csf多肽和其用途
DK2314609T3 (en) * 2008-07-30 2017-03-13 Takeda Pharmaceuticals Co METASTIN DERIVATIVES AND USE THEREOF
US8273343B2 (en) * 2008-07-31 2012-09-25 Pharmaessentia Corp. Protein-polymer conjugates
KR101671537B1 (ko) 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
JP5766118B2 (ja) 2008-09-11 2015-08-19 ウェルズ ファーゴ バンク ナショナル アソシエイション ポリマー性アルファ−ヒドロキシアルデヒドおよびケトン反応剤ならびに抱合方法
PT2337846T (pt) 2008-09-26 2018-04-05 Ambrx Inc Vacinas e microrganismos dependentes da replicação de aminoácidos não naturais
CA2737026C (en) 2008-09-26 2019-12-24 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
CN102227443B (zh) 2008-10-01 2014-05-14 昆特森斯生物科学公司 治疗性核糖核酸酶
KR101651703B1 (ko) 2008-10-10 2016-08-26 암젠 인크 Ｆｇｆ21 돌연변이체 및 이의 용도
US8143347B2 (en) 2008-10-15 2012-03-27 Baxter International Inc. Pegylation of recombinant blood coagulation factors in the presence of bound antibodies
MX2011004085A (es) 2008-10-17 2011-09-27 Baxter International Factores sanguineos modificados que comprenden un bajo grado de polimero soluble en agua.
EP2337794B1 (en) * 2008-10-20 2013-07-31 USV Limited An improved process for pegylation of proteins
DK2431741T3 (da) * 2008-10-21 2013-10-21 Baxter Int Fremgangsmåde til bestemmelse af virksomme bestanddele i profarmaka-PEG-proteinkonjugat
CA2742064A1 (en) * 2008-10-31 2010-05-06 Amgen Inc. Materials and methods relating to stem cell mobilization by multi-pegylated granulocyte colony stimulating factor
IT1392655B1 (it) 2008-11-20 2012-03-16 Bio Ker S R L Site-specific monoconjugated insulinotropic glp-1 peptides.
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
CN102307993B (zh) 2008-12-09 2014-06-25 哈洛齐梅公司 延长的可溶性ph20多肽及其用途
AU2009324447B2 (en) * 2008-12-11 2016-02-25 Takeda Pharmaceutical Company Limited Detection of physiologically acceptable polymer molecules using near infrared spectroscopy
CN103601800B (zh) 2008-12-17 2015-10-21 默沙东公司 单和双peg il10的生产和用途
EP2416763A4 (en) 2009-04-06 2015-05-06 Mayo Foundation PROCESS AND MATERIALS FOR THE RELEASE OF MOLECULES
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
UY38740A (es) 2009-05-05 2020-12-31 Amgen Inc Mutantes de fgf21 y usos del mismo
WO2010129600A2 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
TWI471137B (zh) 2009-05-20 2015-02-01 Biomarin Pharm Inc Ｃ型利鈉胜肽變異體
WO2010148142A1 (en) 2009-06-17 2010-12-23 Amgen Inc. Chimeric fgf19 polypeptides and uses thereof
BRPI1014942A2 (pt) 2009-06-19 2019-09-24 Medimmune Llc "polipeptídeo, ácido nucleico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição farmacêutica, e método para tratar uma doença"
RU2535038C2 (ru) 2009-06-25 2014-12-10 Криэлта Фармасьютикалз ЭлЭлСи Способы и наборы для прогнозирования риска инфузионных реакций и опосредованной антителами потери ответа при терапии пэгилированной уриказой с помощью мониторинга содержания мочевой кислоты в сыворотке крови
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
CA2774053C (en) 2009-09-17 2015-04-28 Baxter Healthcare, S.A. Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
JP5885664B2 (ja) 2009-09-25 2016-03-15 ゾーマ テクノロジー リミテッド スクリーニング法
WO2011037896A2 (en) * 2009-09-25 2011-03-31 Vybion, Inc. Polypeptide modification
US9315860B2 (en) 2009-10-26 2016-04-19 Genovoxx Gmbh Conjugates of nucleotides and method for the application thereof
JP2013508425A (ja) 2009-10-30 2013-03-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｉ２０１３３５、インターフェロンアルファおよびリバビリンを含むｈｃｖの併用療法のための投薬処置計画
CA2778678A1 (en) 2009-10-30 2011-05-05 Cns Therapeutics, Inc. Improved neurturin molecules
AU2010321587A1 (en) 2009-11-23 2012-06-07 Amylin Pharmaceuticals, Inc. Polypeptide Conjugate
US10584181B2 (en) 2009-12-04 2020-03-10 Genentech, Inc. Methods of making and using multispecific antibody panels and antibody analog panels
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
EP2516455A4 (en) 2009-12-21 2013-05-22 Ambrx Inc MODIFIED SWINE SOMATOTROPIN POLYPEPTIDES AND THEIR USES
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
JP5914363B2 (ja) 2010-02-16 2016-05-11 ノヴォ ノルディスク アー／エス 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子
WO2011109556A2 (en) * 2010-03-04 2011-09-09 Pfenex Inc. Method for producing soluble recombinant interferon protein without denaturing
WO2011123570A2 (en) 2010-04-01 2011-10-06 Pfenex Inc. Methods for g-csf production in a pseudomonas host cell
EP2558497A2 (en) 2010-04-15 2013-02-20 Amgen Inc. Human fgf receptor and beta-klotho binding proteins
AU2011248625B2 (en) 2010-04-26 2017-01-05 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
WO2011139799A2 (en) 2010-04-27 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
EP2563911B1 (en) 2010-04-28 2021-07-21 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
JP5991963B2 (ja) 2010-04-29 2016-09-14 エータイアー ファーマ， インコーポレイテッド バリルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
AU2011248490B2 (en) 2010-04-29 2016-11-10 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
CN102234310B (zh) * 2010-04-30 2017-02-08 杭州九源基因工程有限公司 一种聚乙二醇修饰蛋白的分离纯化方法
WO2011140132A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
AU2011248355B2 (en) 2010-05-03 2017-01-19 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Arginyl-tRNA synthetases
JP6008841B2 (ja) 2010-05-03 2016-10-19 エータイアー ファーマ， インコーポレイテッド メチオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
WO2011140267A2 (en) 2010-05-04 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
WO2011143274A1 (en) 2010-05-10 2011-11-17 Perseid Therapeutics Polypeptide inhibitors of vla4
CA2799197C (en) 2010-05-14 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
US8927488B2 (en) 2010-05-17 2015-01-06 Cebix, Inc. Pegylated C-peptide
WO2011146410A2 (en) 2010-05-17 2011-11-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases
EP2576615B1 (en) 2010-05-26 2016-03-30 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
JP6046607B2 (ja) 2010-05-27 2016-12-21 エータイアー ファーマ， インコーポレイテッド グルタミニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
AU2011261486B2 (en) 2010-06-01 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-tRNA synthetases
CN102711871A (zh) 2010-06-16 2012-10-03 麦德托尼克公司 用于稳定药物递送装置中的药物的阻尼系统
JP2013529627A (ja) 2010-06-24 2013-07-22 パンメド リミテッド ヒドロキシクロロキンまたはヒドロキシクロロキンおよび抗ウイルス剤の組合せを使用するｃ型肝炎ウイルス関連疾患の処置
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
CN102971006A (zh) 2010-07-15 2013-03-13 诺沃—诺迪斯克有限公司 稳定的因子viii变体
DK2595624T3 (en) 2010-07-20 2018-03-26 Halozyme Inc Methods of treating or preventing adverse side effects associated with administration of an anti-hyaluronan agent
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2446173C1 (ru) * 2010-08-13 2012-03-27 Зао "Биокад" Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
EP2605789B1 (en) 2010-08-17 2019-06-05 Ambrx, Inc. Modified relaxin polypeptides and their uses
CA2808539C (en) 2010-08-25 2021-05-25 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases
CN103209992A (zh) 2010-09-15 2013-07-17 诺沃—诺迪斯克有限公司 具有减少的细胞摄取的因子viii变体
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
CA2813087C (en) 2010-09-28 2020-07-21 Amylin Pharmaceuticals, Llc Engineered polypeptides having enhanced duration of action
KR20140035305A (ko) 2010-10-05 2014-03-21 노파르티스 아게 C형 간염 바이러스 감염의 새로운 치료법
CA2811799A1 (en) 2010-10-08 2012-04-12 Novartis Ag Vitamin e formulations of sulfamide ns3 inhibitors
CN102453089B (zh) * 2010-10-25 2014-06-04 北京凯因科技股份有限公司 重组集成干扰素变异体聚乙二醇偶联物的制备和应用
CN103933577B (zh) * 2010-10-25 2014-12-10 北京凯因科技股份有限公司 重组集成干扰素变异体聚乙二醇偶联物的制备和应用
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
DK2643019T3 (en) 2010-11-24 2019-04-15 Lexicon Pharmaceuticals Inc ANTIBODIES AGAINST NOTE PECTINACETYL ESTERASE
BR112013013166A2 (pt) 2010-11-30 2016-09-06 Novartis Ag tratamentos da infecção pelo vírus da hepatite c
CN102485742A (zh) * 2010-12-02 2012-06-06 山东新时代药业有限公司 一种聚乙二醇单修饰的重组人粒细胞集落刺激因子的制备及分离纯化方法
US20140371258A1 (en) 2010-12-17 2014-12-18 Nektar Therapeutics Water-Soluble Polymer Conjugates of Topotecan
JP5899241B2 (ja) 2010-12-21 2016-04-06 ネクター セラピューティクス ペメトレキセドベースの化合物のマルチアームポリマープロドラッグコンジュゲート
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
JP2014510045A (ja) 2011-02-08 2014-04-24 ハロザイム インコーポレイテッド ヒアルロナン分解酵素の組成物および脂質製剤ならびに良性前立腺肥大症の治療のためのその使用
SG10201601789TA (en) 2011-03-16 2016-04-28 Amgen Inc Potent And Selective Inhibitors Of Nav1.3 And Nav1.7
CA2830664A1 (en) * 2011-03-25 2012-10-04 The Trustees Of Columbia University In The City Of New York Pegylated human hdl particle and process for production thereof
EP2691094A1 (en) 2011-03-31 2014-02-05 Novartis AG Alisporivir to treat hepatitis c virus infection
DK2694087T3 (en) 2011-04-01 2015-04-13 Novartis Ag The treatment of infection with Hepatitis B virus alone or in combination with hepatitis delta virus, and in connection with liver diseases
US20150104415A1 (en) 2011-04-13 2015-04-16 Debiopharm International Sa Treatments of Hepatitis C virus infection
US20140187488A1 (en) 2011-05-17 2014-07-03 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
LT2714735T (lt) 2011-06-03 2021-12-10 Xoma Technology Ltd. Tgf beta specifiniai antikūnai
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
WO2012174480A2 (en) 2011-06-17 2012-12-20 Halozyme, Inc. Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
US20130090294A1 (en) 2011-06-28 2013-04-11 Alternative Innovative Technologies Llc Novel methods of use of hsp70 for increased performance or treatment of hsp70 related disorders
WO2013004607A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
JP6208658B2 (ja) 2011-07-05 2017-10-04 バイオアシス テクノロジーズ インコーポレイテッド ｐ９７−抗体結合体および使用方法
DK2729160T3 (da) 2011-07-08 2019-07-01 Aegerion Pharmaceuticals Inc Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet
CN102952067A (zh) * 2011-08-30 2013-03-06 苏州欣诺科生物科技有限公司 用于蛋白质n端聚乙二醇修饰的吡哆醛衍生物、制备方法及其应用
JP2014526441A (ja) 2011-08-31 2014-10-06 アムジエン・インコーポレーテツド １型糖尿病の治療における使用のためのｆｇｆ２１
US20130071394A1 (en) 2011-09-16 2013-03-21 John K. Troyer Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
US9458214B2 (en) 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
JO3476B1 (ar) 2011-09-26 2020-07-05 Novartis Ag بروتينات مندمجة لعلاج الاضطرابات الايضية
KR20140070565A (ko) 2011-09-27 2014-06-10 노파르티스 아게 C형 간염 바이러스 감염의 치료를 위한 알리스포리비르
RU2014114849A (ru) 2011-10-14 2015-11-20 Алтернатив Инновейтив Текнолоджиз Ллц Устойчивые к деградации производные белков теплового шока-70 (бтш70) и способы их применения (варианты)
MX342735B (es) 2011-10-24 2016-10-07 Halozyme Inc Diagnostico acompañante para terapia con agente anti-hialuronano y metodos de uso del mismo.
US10350139B2 (en) 2011-10-25 2019-07-16 Corning Incorporated Pharmaceutical glass packaging assuring pharmaceutical sterility
WO2013063277A1 (en) 2011-10-25 2013-05-02 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
WO2013067029A2 (en) 2011-10-31 2013-05-10 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
CN104220086A (zh) 2011-11-17 2014-12-17 塞比克斯股份公司 Peg化的c-肽
WO2013101509A2 (en) 2011-12-15 2013-07-04 Alternative Innovative Technologies Llc Hsp70 fusion protein conjugates and uses thereof
CN104244968B (zh) 2011-12-30 2017-07-25 哈洛齐梅公司 Ph20多肽变体、配制物及其应用
CA2861402C (en) 2012-01-30 2021-10-12 Guy Casy Stabilized aqueous antibody compositions
DK2814514T3 (en) 2012-02-16 2017-12-18 Atyr Pharma Inc Histidyl tRNA synthetases for the treatment of autoimmune and inflammatory diseases
CA3179537A1 (en) 2012-02-27 2013-09-06 Amunix Pharmaceuticals, Inc. Xten conjugate compositions and methods of making same
EP2821079A4 (en) 2012-02-29 2016-05-04 Toray Industries MEANS FOR SUPPRESSING BODY CAVITIES
EP2822575B1 (en) 2012-03-03 2020-05-06 ImmunGene, Inc. Engineered antibody-interferon mutant fusion molecules
WO2013137869A1 (en) 2012-03-14 2013-09-19 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
WO2013143581A1 (en) 2012-03-28 2013-10-03 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in specific patient subgenotype sub-population
CN104411332B (zh) 2012-03-30 2018-11-23 索伦托治疗有限公司 与vegfr2结合的全人抗体
SMT201800366T1 (it) 2012-04-04 2018-09-13 Halozyme Inc Combinazione terapia con ialuronidasi e taxano mirato al tumore
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
ES2718478T3 (es) 2012-06-08 2019-07-02 Sutro Biopharma Inc Anticuerpos que comprenden restos de aminoácidos no naturales de localización específica, métodos para su preparación y métodos para su uso
HK1208236A1 (en) 2012-06-22 2016-02-26 Sorrento Therapeutics, Inc. Antigen binding proteins that bind ccr2
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
JP6433424B2 (ja) 2012-07-31 2018-12-05 バイオアシス テクノロジーズ インコーポレイテッド 脱リン酸化されたリソソーム蓄積症タンパク質およびその使用方法
AU2013308494B2 (en) 2012-08-31 2018-03-01 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
CN104884056A (zh) 2012-11-12 2015-09-02 雷德伍德生物科技股份有限公司 用于制备缀合物的化合物和方法
US9605078B2 (en) 2012-11-16 2017-03-28 The Regents Of The University Of California Pictet-Spengler ligation for protein chemical modification
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
US9383357B2 (en) 2012-12-07 2016-07-05 Northwestern University Biomarker for replicative senescence
US20160067347A1 (en) 2012-12-20 2016-03-10 Amgen Inc. Apj receptor agonists and uses thereof
CN103908660B (zh) * 2013-01-05 2015-02-04 石药集团百克(山东)生物制药有限公司 一种聚乙二醇修饰的rhG-CSF药物组合物及其制备方法
US20150361159A1 (en) 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
CN103113466B (zh) * 2013-03-01 2015-06-03 中国科学院过程工程研究所 聚乙二醇修饰的重组人干扰素β-1b及制备方法
TW201446792A (zh) 2013-03-12 2014-12-16 Amgen Inc Nav1．7之強效及選擇性抑制劑
CN105263958B (zh) 2013-03-13 2019-09-27 比奥阿赛斯技术有限公司 p97片段及其应用
RU2535002C2 (ru) * 2013-04-04 2014-12-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство коррекции отдаленных последствий нарушений сперматогенеза, вызванных цитостатическим воздействием
CA2908198A1 (en) 2013-04-18 2014-10-23 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US9707155B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717649B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9713572B2 (en) 2013-04-24 2017-07-25 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707153B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717648B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9839579B2 (en) 2013-04-24 2017-12-12 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
EP3434277A1 (en) 2013-06-17 2019-01-30 Armo Biosciences, Inc. Method for assessing protein identity and stability
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
ES2865473T3 (es) 2013-07-10 2021-10-15 Sutro Biopharma Inc Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
JP6509867B2 (ja) 2013-08-30 2019-05-08 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためにインターロイキン−１０を使用する方法
EP3052123A1 (en) 2013-10-02 2016-08-10 Novartis Ag Insulin-like growth factor mimetics for use in therapy
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
WO2015057908A1 (en) 2013-10-18 2015-04-23 Novartis Ag Methods of treating diabetes and related disorders
RU2016122957A (ru) 2013-11-11 2017-12-19 Армо Байосайенсиз, Инк. Способы применения интерлейкина-10 для лечения заболеваний и расстройств
US20160296632A1 (en) 2013-11-13 2016-10-13 Aequus Biopharma, Inc. Engineered glycoproteins and uses thereof
CN105744935B (zh) 2013-11-27 2022-09-30 雷德伍德生物科技股份有限公司 肼基-吡咯并化合物及用于生成缀合物的方法
UY35874A (es) 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas
US10188739B2 (en) 2014-02-27 2019-01-29 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
CN106573072A (zh) 2014-06-02 2017-04-19 阿尔莫生物科技股份有限公司 降低血清胆固醇的方法
JP6803236B2 (ja) 2014-06-10 2020-12-23 アムジェン インコーポレイテッド アペリンポリペプチド
PL3154561T3 (pl) 2014-06-12 2019-12-31 Ra Pharmaceuticals, Inc. Modulowanie aktywności dopełniacza
WO2016028523A2 (en) 2014-08-22 2016-02-25 Sorrento Therapeutics, Inc. Antigen binding proteins that bind cxcr3
DK3186281T3 (da) 2014-08-28 2019-06-11 Halozyme Inc Kombinationsterapi med et hyaluronan-nedbrydende enzym og en immun-checkpoint-inhibitor
CN107001438A (zh) 2014-10-14 2017-08-01 阿尔莫生物科技股份有限公司 白细胞介素‑15组合物及其用途
EA201700181A1 (ru) 2014-10-14 2017-09-29 Галозим, Инк. Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
CN107106655A (zh) 2014-10-22 2017-08-29 阿尔莫生物科技股份有限公司 使用白细胞介素‑10治疗疾病和病症的方法
KR102854572B1 (ko) 2014-10-24 2025-09-02 브리스톨-마이어스 스큅 컴퍼니 변형된 fgf-21 폴리펩티드 및 그의 용도
ES2966888T3 (es) 2014-11-06 2024-04-24 Pharmaessentia Corp Régimen de dosificación para el interferón pegilado
US20160151511A1 (en) 2014-12-02 2016-06-02 Antriabio, Inc. Proteins and protein conjugates with increased hydrophobicity
CN104491843B (zh) * 2015-01-23 2017-09-12 石药集团百克(山东)生物制药有限公司 一种聚乙二醇修饰的rhG‑CSF活性药物组合物
HRP20211824T1 (hr) 2015-01-28 2022-03-04 Ra Pharmaceuticals, Inc. Modulatori aktivnosti komplementa
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10711067B2 (en) 2015-03-03 2020-07-14 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
CN107849108A (zh) * 2015-03-03 2018-03-27 阿瓦隆生物制品有限公司 聚乙二醇化的il‑11的组合物和方法
CN108136001B (zh) 2015-04-03 2022-07-29 佐马技术有限公司 使用TGF-β抑制剂和PD-1抑制剂治疗癌症
JP6525171B2 (ja) 2015-04-13 2019-06-05 国立研究開発法人産業技術総合研究所 環状化サイトカイン及びその製法
CN107530396B (zh) 2015-05-01 2022-08-26 雅利斯塔制药公司 用于治疗眼科疾病的脂联素拟肽
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
KR20180020141A (ko) 2015-05-28 2018-02-27 아르모 바이오사이언시스 인코포레이티드 암 치료에 사용되는 peg화된 인터류킨-10
AU2016304588A1 (en) 2015-08-06 2018-02-15 Xoma (Us) Llc Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
KR20180038553A (ko) 2015-08-25 2018-04-16 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
CN114805540A (zh) * 2015-09-18 2022-07-29 国立大学法人宫崎大学 长效肾上腺髓质素衍生物
EP3355908A1 (en) 2015-10-01 2018-08-08 Amgen Inc. Treatment of bile acid disorders
US10935276B2 (en) 2015-10-20 2021-03-02 Steven Michalski Air mixing device
CN108463226B (zh) 2015-11-09 2022-04-15 R.P.谢勒技术有限责任公司 抗cd22抗体-美登木素缀合物及其使用方法
PL3386531T3 (pl) 2015-12-08 2022-02-28 Biomarin Pharmaceutical Inc. Zastosowanie wariantów peptydu natriuretycznego typu c w leczeniu choroby zwyrodnieniowej stawów
RS60134B1 (sr) 2015-12-16 2020-05-29 Ra Pharmaceuticals Inc Modulatori aktivnosti komplementa
BR112018015480A2 (pt) 2016-01-29 2019-05-21 Sorrento Therapeutics, Inc. proteínas de ligação ao antígeno que se ligam a pd-l1
WO2017180998A2 (en) 2016-04-15 2017-10-19 Beckman Coulter, Inc. Photoactive macromolecules and uses thereof
WO2018026748A1 (en) 2016-08-01 2018-02-08 Xoma (Us) Llc Parathyroid hormone receptor 1 (pth1r) antibodies and uses thereof
JP2019534710A (ja) 2016-09-28 2019-12-05 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー インターロイキン２に結合する抗体およびその使用
CN110234340A (zh) 2016-11-11 2019-09-13 好利恩风湿病制药有限责任公司 泼尼松和尿酸酶分子的组合疗法及其用途
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
BR112019011053A2 (pt) 2016-12-07 2019-10-15 Ra Pharmaceuticals Inc moduladores da atividade do complemento
BR112019016139A2 (pt) 2017-02-08 2020-04-07 Bristol-Myers Squibb Company polipeptídio de relaxina modificada compreendendo um melhorador farmacocinético e usos do mesmo
BR112019027583A2 (pt) 2017-06-22 2020-10-06 Catalyst Biosciences, Inc. polipeptídeos de serina protease 1 tipo membrana (mtsp-1) modificados e métodos de uso
KR102020995B1 (ko) 2017-10-30 2019-09-16 한국코러스 주식회사 콜로니자극인자와 폴리올이 접합된 접합물을 고수율로 제조하는 방법
US11492493B2 (en) 2017-12-26 2022-11-08 Becton, Dickinson And Company Deep ultraviolet-excitable water-solvated polymeric dyes
JP2021509805A (ja) 2017-12-27 2021-04-08 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ 顆粒球コロニー刺激因子活性を示すポリペプチド
EP3765484A4 (en) * 2018-03-14 2021-12-22 Ba, Yong PEGYLATED ANTIFREEZE PROTEINS AND PROCESSES FOR PREPARATION AND USE
CN112384573A (zh) 2018-03-30 2021-02-19 贝克顿·迪金森公司 含侧基发色团的水溶性聚合染料
CN119345105A (zh) 2018-04-24 2025-01-24 安进公司 用于制备可注射药物组合物的方法
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
KR102167755B1 (ko) 2018-05-23 2020-10-19 주식회사 큐어바이오 단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도
WO2020023300A1 (en) 2018-07-22 2020-01-30 Bioasis Technologies, Inc. Treatment of lymmphatic metastases
WO2020056066A1 (en) 2018-09-11 2020-03-19 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
AU2019361206A1 (en) 2018-10-19 2021-06-03 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
JP7604376B2 (ja) 2018-12-28 2024-12-23 バーテックス ファーマシューティカルズ インコーポレイテッド 改変ウロキナーゼ型プラスミノゲンアクティベータポリペプチドおよび使用方法
WO2020160325A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
WO2020160322A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
WO2020168017A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
US10882954B2 (en) 2019-04-11 2021-01-05 Sunbio Inc. Tertiary alkoxy polyethylene glycol and derivatives thereof
US12448488B2 (en) 2019-04-15 2025-10-21 Nof Corporation Conjugate of bio-related substance and block polymer, and block polymer derivative for obtaining said conjugate
CA3136602A1 (en) 2019-04-15 2020-10-22 Qwixel Therapeutics Llc Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
CN120682337A (zh) 2020-03-11 2025-09-23 北京泰德制药股份有限公司 白介素-2多肽偶联物及其使用方法
CA3171491A1 (en) 2020-03-20 2021-09-23 Amgen, Inc. Determination of free n-terminus of pegfilgrastim using an acid protease
US20210355468A1 (en) 2020-05-18 2021-11-18 Bioasis Technologies, Inc. Compositions and methods for treating lewy body dementia
US20210393787A1 (en) 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
TW202227449A (zh) 2020-08-20 2022-07-16 美商Ａｍｂｒｘ 公司 抗體－ｔｌｒ促效劑偶聯物、其方法及用途
US11602598B1 (en) 2020-08-27 2023-03-14 Fresenius Kabi Deutschland Gmbh Prefilled syringe with pegfilgrastim having optimized dose and methods related thereto
CN112710826A (zh) * 2020-11-17 2021-04-27 北京九强生物技术股份有限公司 一种提高试剂稳定性的包被和封闭方法
US11952461B2 (en) 2021-03-22 2024-04-09 Sunbio, Inc. Siloxy polyethylene glycol and derivatives thereof
MX2023011480A (es) 2021-04-03 2023-12-06 Ambrx Inc Conjugados anticuerpo anti-her2-fármaco y usos de estos.
CN113214328B (zh) * 2021-05-08 2022-06-28 宁波经济技术开发区弘翔生化科技有限公司 一种双水相体系以及基于双水相体系的单糖分离方法
EP4155349A1 (en) 2021-09-24 2023-03-29 Becton, Dickinson and Company Water-soluble yellow green absorbing dyes
JP2025522834A (ja) 2022-07-01 2025-07-17 ベックマン コールター， インコーポレイテッド ジヒドロフェナントレン誘導体からの新規な蛍光染料およびポリマー
WO2024044327A1 (en) 2022-08-26 2024-02-29 Beckman Coulter, Inc. Dhnt monomers and polymer dyes with modified photophysical properties
WO2024196805A1 (en) 2023-03-17 2024-09-26 Beckman Coulter, Inc. Benzothienopyrrole cyanine dyes
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers
WO2025064842A1 (en) 2023-09-21 2025-03-27 Beckman Coulter, Inc. Dihydrophenanthrene (dhp) bridged dyes for use in flow cytometry
WO2025227129A2 (en) 2024-04-25 2025-10-30 Starrock Pharma Llc Delivery vehicles comprising proglucagon derived polypeptides and anabolic polypeptides and uses thereof
US20250341516A1 (en) 2024-05-01 2025-11-06 BioLegend, Inc. Compositions for use with multiple fluorophores and methods of using

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1609546A (en) * 1925-11-19 1926-12-07 Petroleum Rectifying Co Process of separating water from emulsions
DE2047413C3 (de) * 1970-09-26 1980-05-29 F. Hoffmann-La Roche & Co Ag, Basel (Schweiz) Verfahren zur Herstellung von Peptiden in homogener Phase
US4002714A (en) * 1972-08-14 1977-01-11 Fumio Usui Method for producing a tapered pipe of reinforced synthetic resin
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
DE2930542A1 (de) 1979-07-27 1981-02-12 Hoechst Ag Neue insulinderivate und verfahren zu ihrer herstellung
JPS57192435A (en) 1981-05-20 1982-11-26 Toyobo Co Ltd Modified polypeptide
DE3139483C2 (de) 1981-10-03 1985-06-13 Dr.-Ing. Rudolf Hell Gmbh, 2300 Kiel Verfahren und Schaltungsanordnung zur Kontraststeigerung
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
JPS58225025A (ja) * 1982-06-24 1983-12-27 Nippon Chem Res Kk 効力持続性組成物
EP0098110B1 (en) * 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
WO1985003934A1 (fr) 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Proteine modifiee chimiquement et son procede de preparation
EP0154316B1 (en) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
JPS6142558A (ja) 1984-08-06 1986-03-01 Matsushita Electric Works Ltd アミノ樹脂成形材料
JPS62129298A (ja) 1985-12-02 1987-06-11 Chugai Pharmaceut Co Ltd 新規ポリペプチド
DE3680613D1 (de) 1985-02-08 1991-09-05 Chugai Pharmaceutical Co Ltd Menschlicher granuloxcyt-kolonie-stimulierungsfaktor.
US5532341A (en) * 1985-03-28 1996-07-02 Sloan-Kettering Institute For Cancer Research Human pluripotent hematopoietic colony stimulating factor
JP2524586B2 (ja) 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
ES8800982A1 (es) 1985-07-05 1987-12-01 Takeda Chemical Industries Ltd Un metodo para producir la enzima superoxido-dismutasa modificada con derivados de polietilenglicol y triazina.
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
JPS62236497A (ja) 1985-09-17 1987-10-16 Chugai Pharmaceut Co Ltd 顆粒球コロニー刺激因子活性を有する糖蛋白質の製造方法
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
DK203187A (da) * 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
US6673347B1 (en) * 1986-04-30 2004-01-06 Gryphon Therapeutics Polypeptide and protein derivatives and process for their preparation
CA1283046C (en) 1986-05-29 1991-04-16 Nandini Katre Tumor necrosis factor formulation
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
JPS63126900A (ja) 1986-06-26 1988-05-30 Takeda Chem Ind Ltd 化学修飾蛋白質
JPS63152393A (ja) 1986-07-03 1988-06-24 Takeda Chem Ind Ltd グリコシル誘導体
GR871067B (en) 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
WO1988001297A1 (en) 1986-08-11 1988-02-25 Cetus Corporation Expression of g-csf and muteins thereof
JPS6360938A (ja) 1986-09-02 1988-03-17 Meiji Milk Prod Co Ltd 修飾組織型プラスミノ−ゲン活性化因子およびその製造方法
US4894226A (en) * 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
NO176799C (no) * 1986-12-23 1995-05-31 Kyowa Hakko Kogyo Kk DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid
US5194592A (en) * 1986-12-23 1993-03-16 Kyowa Hakko Kogyo Co. Ltd. Monoclonal antibodies to novel polypeptide derivatives of human granulocyte colony stimulating factor
US5214132A (en) * 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5362853A (en) * 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
JPH086063B2 (ja) 1987-07-22 1996-01-24 日本ペイント株式会社 親水性表面処理剤及び処理方法
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
CA1340810C (en) * 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
JP2958019B2 (ja) 1988-05-06 1999-10-06 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
ATE452190T1 (de) * 1988-05-13 2010-01-15 Amgen Inc Verfahren zur isolierung und reinigung von g-csf
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
JPH04502011A (ja) 1988-11-23 1992-04-09 ジェネンテク，インコーポレイテッド ポリペプチド誘導体
US6166183A (en) * 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
CA2006596C (en) * 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
CA2047730A1 (en) 1989-02-24 1990-08-25 Carl W. Gilbert Immobilized cytokines
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
KR920701252A (ko) * 1989-10-10 1992-08-11 스티븐 엠. 오드레 과립구 군체 자극인자 및 그를 이용하여 개 및 고양이과 동물의 전염병을 치료하거나 예방하는 방법
JP2978187B2 (ja) 1989-11-02 1999-11-15 日本ケミカルリサーチ株式会社 修飾スーパーオキサイドディスムターゼの製造法
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
DE4009661C1 (OSRAM) 1990-03-26 1991-03-07 Aisa Automation Industrielle S.A., Vouvry, Ch
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (de) * 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
ES2128348T3 (es) * 1990-10-17 1999-05-16 Amgen Inc Obtencion de composiciones para el tratamiento de alteraciones de la proliferacion celular.
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5124297A (en) 1990-12-07 1992-06-23 Amoco Corporation Olefin polymerization and copolymerization catalyst
CH682636A5 (de) * 1990-12-21 1993-10-29 Bucher Guyer Ag Masch Verfahren zum selektiven Entfernen von Zucker aus Getränken.
SG63617A1 (en) 1991-01-18 1999-03-30 Amgen Boulder Inc Methods for treating tumar necrosis factor mediated diseases
DE4105480A1 (de) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
CA2106079C (en) 1991-03-15 2000-04-25 Robert C. Thompson Pegylation of polypeptides
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
WO1993000109A1 (en) 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5197592A (en) * 1991-08-05 1993-03-30 Fmc Corporation Wire frame idler roll support
NZ244778A (en) * 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
US5589365A (en) * 1991-11-29 1996-12-31 Banyu Pharmaceutical Co., Ltd. Process for producing glycosylated indolopyrrolocarbazole derivatives by culturing certain microorganisms
JP3235855B2 (ja) 1991-12-19 2001-12-04 住友製薬株式会社 細胞接着活性ペプチド及びその高分子修飾体
JP3387519B2 (ja) * 1992-03-04 2003-03-17 株式会社日立製作所 情報記録再生方式及びデイスク状記録媒体
FR2692736B1 (fr) 1992-06-23 1996-12-20 Thomson Csf Filtre radioelectrique de forte et moyenne puissance.
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
AU6048294A (en) 1992-11-25 1994-06-22 Amgen Boulder Inc. Modified insulin-like growth factors
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5589356A (en) * 1993-06-21 1996-12-31 Vanderbilt University Litigation of sidechain unprotected peptides via a masked glycoaldehyde ester and O,N-acyl rearrangement
WO1995000162A1 (en) * 1993-06-21 1995-01-05 Enzon, Inc. Site specific synthesis of conjugated peptides
US5481571A (en) 1993-11-12 1996-01-02 Pacific Communication Sciences, Inc. Method and apparatus for switching between radio frequency circuits
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
TW496870B (en) * 1994-03-31 2002-08-01 Amgen Inc Compositions methods for stimulating megakaryocyte growth and differentiation
US5646113A (en) * 1994-04-07 1997-07-08 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US5935924A (en) * 1994-04-15 1999-08-10 Genentech, Inc. Treatment of congestive heart failure
US5661122A (en) * 1994-04-15 1997-08-26 Genentech, Inc. Treatment of congestive heart failure
AU2601895A (en) 1994-05-24 1995-12-18 Amgen Boulder Inc. Modified insulin-like growth factors
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
JP3708151B2 (ja) 1994-12-15 2005-10-19 協和醗酵工業株式会社 Ｐｅｇ化したヒト顆粒球コロニー刺激因子の定量法
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
KR101441331B1 (ko) 2013-07-19 2014-09-17 주식회사 슈프리마 광학식 지문 인식 장치

Also Published As

Publication number Publication date
JP2003327600A (ja) 2003-11-19
JP3177449B2 (ja) 2001-06-18
IL134754A (en) 2009-11-18
JP2006045243A (ja) 2006-02-16
NL300106I2 (nl) 2003-02-03
MX9602259A (es) 1997-02-28
US20120296072A1 (en) 2012-11-22
JP3177251B2 (ja) 2001-06-18
US8258262B2 (en) 2012-09-04
ES2131811T3 (es) 1999-08-01
US20100310510A1 (en) 2010-12-09
US5985265A (en) 1999-11-16
JP5350330B2 (ja) 2013-11-27
CA2178752C (en) 2000-10-17
CN101381409A (zh) 2009-03-11
EP0822199B1 (en) 2004-09-22
CN1896103A (zh) 2007-01-17
KR100261030B1 (en) 2000-06-15
GR3030526T3 (en) 1999-10-29
CA2178752A1 (en) 1996-04-25
CA2307142C (en) 2010-09-21
US20130189219A1 (en) 2013-07-25
CA2472085A1 (en) 1996-04-25
JP2010215657A (ja) 2010-09-30
CA2307142A1 (en) 1996-04-25
CN1071760C (zh) 2001-09-26
US7662933B2 (en) 2010-02-16
PT822199E (pt) 2005-01-31
NZ281469A (en) 1997-04-24
US5824784A (en) 1998-10-20
ATE277078T1 (de) 2004-10-15
CN1229388C (zh) 2005-11-30
EP0822199A3 (en) 2001-10-24
IL112585A (en) 2000-08-31
IL112585A0 (en) 1995-05-26
IL134754A0 (en) 2001-04-30
CN101381409B (zh) 2013-03-27
US7090835B2 (en) 2006-08-15
DE69533556D1 (de) 2004-10-28
ES2224197T3 (es) 2005-03-01
EP2392594A1 (en) 2011-12-07
EP0733067B1 (en) 1999-05-12
DK0733067T3 (da) 1999-11-01
US20060233746A1 (en) 2006-10-19
ATE179991T1 (de) 1999-05-15
AU706700B2 (en) 1999-06-24
AU1841995A (en) 1996-05-06
JPH0925298A (ja) 1997-01-28
EP0733067A1 (en) 1996-09-25
JPH11310600A (ja) 1999-11-09
DE69509628T2 (de) 1999-09-16
JPH09506116A (ja) 1997-06-17
JP2006077021A (ja) 2006-03-23
US20040181035A1 (en) 2004-09-16
EP1564219A1 (en) 2005-08-17
EP2399930A1 (en) 2011-12-28
CN1139932A (zh) 1997-01-08
WO1996011953A1 (en) 1996-04-25
HK1008787A1 (en) 1999-05-21
DE69533556T2 (de) 2005-10-20
DE10299044I1 (de) 2003-03-27
EP0822199A2 (en) 1998-02-04
HK1008826A1 (en) 1999-05-21
NL300106I1 (nl) 2003-01-06
JP2003155299A (ja) 2003-05-27
CN1313343A (zh) 2001-09-19
KR100248111B1 (ko) 2000-03-15
ZA951008B (en) 1996-10-18
DE69509628D1 (de) 1999-06-17

Similar Documents

Publication Publication Date Title
LU91006I2 (en) Neupopeg-pegfilgrastim et ses dérivés pharmaceutiquement acceptables
ATE152172T1 (de) Herstellung eines rekombinanten menschlichen interleukin-1-hemmers
AU561016B2 (en) N-glycosylated carboxamide derivatives
IE851623L (en) Substituted benzamides
IE880704L (en) Substituted benzamides.
PT80191A (en) Process for preparing substituted benzopyrans useful as medicaments
HUP9802206A1 (hu) Thalidomid intravénás adagolási formája immunológiai megbetegedések gyógyításához
WO1999014241A3 (en) Compositions and methods for the treatment of immune related diseases
EP0249247A3 (en) Purine derivatives
EP0207564A3 (en) Process for the synthesis of organofunctional silanes using isatoic anhydride or derivatives thereof
GR3006438T3 (OSRAM)
WO2000015797A3 (en) Compositions and methods for the treatment of immune related diseases
BG90414A (bg) 2-азабицикло (2,2,1)-хепт-5- ен-2-оцетна киселина и нейни производни, метод за получаване и приложението им
DE3464609D1 (en) Spiro(benzofuran-azalkanes), a method for their preparation and their use as medicaments
ES2096559T3 (es) Interferon gamma humano, procedimiento para la preparacion de dicho interferon gamma humano, y su uso.
AU563990B2 (en) Hexahydropyrrolo (2,1-a) isoquinoline derivatives
FR2696746B1 (fr) Dérivés de l'acide benzèneborinique, leur préparation et leur utilisation comme intermédiaires de synthèse.
EP0284510A3 (en) N-[N alpha-(1(S)-carboxy-3-cyclohexyl-propyl)-1-lysyl] N-cyclopentylglycine as antihypertensives